Editas Medicine Inc (NASDAQ:EDIT) CFO Andrew A. F. Hack sold 6,000 shares of the firm’s stock in a transaction on Friday, March 16th. The shares were sold at an average price of $39.43, for a total transaction of $236,580.00. Following the completion of the sale, the chief financial officer now owns 6,000 shares in the company, valued at $236,580. The sale was disclosed in a document filed with the SEC, which is available at this link.
Shares of Editas Medicine stock opened at $39.24 on Thursday. Editas Medicine Inc has a one year low of $13.12 and a one year high of $45.02. The company has a debt-to-equity ratio of 0.16, a quick ratio of 9.05 and a current ratio of 9.05. The company has a market cap of $1,788.19, a price-to-earnings ratio of -13.17 and a beta of 3.68.
Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Tuesday, March 6th. The company reported ($0.84) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by ($0.09). Editas Medicine had a negative return on equity of 61.92% and a negative net margin of 876.49%. The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $4.25 million. During the same quarter in the prior year, the business earned ($1.10) earnings per share. Editas Medicine’s revenue was up 311.1% compared to the same quarter last year. analysts predict that Editas Medicine Inc will post -3.3 earnings per share for the current fiscal year.
A number of equities research analysts have recently weighed in on the stock. Barclays raised their price objective on shares of Editas Medicine from $28.00 to $46.00 and gave the company an “overweight” rating in a report on Wednesday, March 7th. CLSA started coverage on shares of Editas Medicine in a report on Tuesday, February 13th. They issued an “underperform” rating on the stock. BidaskClub lowered shares of Editas Medicine from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Morgan Stanley reiterated an “equal weight” rating and set a $43.00 price target (up from $28.00) on shares of Editas Medicine in a research note on Wednesday, March 14th. Finally, Zacks Investment Research upgraded shares of Editas Medicine from a “sell” rating to a “hold” rating in a research note on Friday, March 9th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company. Editas Medicine has a consensus rating of “Hold” and an average target price of $42.17.
A number of large investors have recently made changes to their positions in EDIT. Great West Life Assurance Co. Can raised its stake in Editas Medicine by 519.9% during the 3rd quarter. Great West Life Assurance Co. Can now owns 4,959 shares of the company’s stock worth $114,000 after acquiring an additional 4,159 shares in the last quarter. Glenmede Trust Co. NA acquired a new stake in Editas Medicine during the 4th quarter worth $153,000. Royal Bank of Canada increased its stake in Editas Medicine by 4.1% in the second quarter. Royal Bank of Canada now owns 9,364 shares of the company’s stock valued at $157,000 after purchasing an additional 372 shares during the period. Martingale Asset Management L P acquired a new position in Editas Medicine in the fourth quarter valued at $219,000. Finally, Plancorp LLC acquired a new position in Editas Medicine in the fourth quarter valued at $235,000. Hedge funds and other institutional investors own 64.49% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://ledgergazette.com/2018/03/22/andrew-a-f-hack-sells-6000-shares-of-editas-medicine-inc-edit-stock.html.
Editas Medicine Company Profile
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.